Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

Apolipoprotein A-I mimetics mitigate intestinal inflammation in COX2-dependent inflammatory bowel disease model.

Meriwether D, Sulaiman D, Volpe C, Dorfman A, Grijalva V, Dorreh N, Solorzano-Vargas RS, Wang J, O'Connor E, Papesh J, Larauche M, Trost H, Palgunachari MN, Anantharamaiah GM, Herschman HR, Martin MG, Fogelman AM, Reddy ST.

J Clin Invest. 2019 Jun 11;130:3670-3685. doi: 10.1172/JCI123700.

2.

Probing membrane enhanced protein-protein interactions in a minimal redox complex of cytochrome-P450 and P450-reductase.

Mahajan M, Ravula T, Prade E, Anantharamaiah GM, Ramamoorthy A.

Chem Commun (Camb). 2019 May 16;55(41):5777-5780. doi: 10.1039/c9cc01630a.

PMID:
31041432
3.

Corrigendum to "Solid-state NMR structural investigations of peptide-based nanodiscs and of transmembrane helices in bicellar arrangements" [Chem. Phys. Lipids 219 (2019) 58-71].

Salnikov ES, Aisenbrey C, Anantharamaiah GM, Bechinger B.

Chem Phys Lipids. 2019 Jul;221:219. doi: 10.1016/j.chemphyslip.2019.04.006. Epub 2019 Apr 26. No abstract available.

PMID:
31036256
4.

Lipoprotein modulation of proteinuric renal injury.

Tsuchida Y, Zhong J, Otsuka T, Dikalova A, Pastan I, Anantharamaiah GM, Linton MF, Yancey PG, Ikizler TA, Fogo AB, Yang H, Kon V.

Lab Invest. 2019 Jul;99(8):1107-1116. doi: 10.1038/s41374-019-0253-6. Epub 2019 Apr 24.

PMID:
31019291
5.

Solid-state NMR structural investigations of peptide-based nanodiscs and of transmembrane helices in bicellar arrangements.

Salnikov ES, Aisenbrey C, Anantharamaiah GM, Bechinger B.

Chem Phys Lipids. 2019 Mar;219:58-71. doi: 10.1016/j.chemphyslip.2019.01.012. Epub 2019 Jan 31. Erratum in: Chem Phys Lipids. 2019 Jul;221:219.

PMID:
30711343
6.

The apoA-I mimetic peptide 4F protects apolipoprotein A-I from oxidative damage.

White CR, Datta G, Wilson L, Palgunachari MN, Anantharamaiah GM.

Chem Phys Lipids. 2019 Mar;219:28-35. doi: 10.1016/j.chemphyslip.2019.01.009. Epub 2019 Jan 29.

PMID:
30707910
7.

Apolipoprotein A1 Forms 5/5 and 5/4 Antiparallel Dimers in Human High-density Lipoprotein.

He Y, Song HD, Anantharamaiah GM, Palgunachari MN, Bornfeldt KE, Segrest JP, Heinecke JW.

Mol Cell Proteomics. 2019 May;18(5):854-864. doi: 10.1074/mcp.RA118.000878. Epub 2019 Jan 18.

PMID:
30659061
8.

Novel fatty acyl apoE mimetic peptides have increased potency to reduce plasma cholesterol in mice and macaques.

Anantharamaiah GM, Garber DW, Goldberg D, Morrel E, Datta G, Palgunachari MN, Register TC, Appt SE, White CR.

J Lipid Res. 2018 Nov;59(11):2075-2083. doi: 10.1194/jlr.M085985. Epub 2018 Sep 10.

9.

Nanodisc-Forming Scaffold Protein Promoted Retardation of Amyloid-Beta Aggregation.

Sahoo BR, Genjo T, Cox SJ, Stoddard AK, Anantharamaiah GM, Fierke C, Ramamoorthy A.

J Mol Biol. 2018 Oct 19;430(21):4230-4244. doi: 10.1016/j.jmb.2018.08.018. Epub 2018 Aug 28.

PMID:
30170005
10.

Supramolecular Organization of Apolipoprotein-A-I-Derived Peptides within Disc-like Arrangements.

Salnikov ES, Anantharamaiah GM, Bechinger B.

Biophys J. 2018 Aug 7;115(3):467-477. doi: 10.1016/j.bpj.2018.06.026. Epub 2018 Jul 11.

11.

The Apolipoprotein E Mimetic Peptide AEM-2 Attenuates Mitochondrial Injury And Apoptosis In Human THP-1 Macrophages.

Giordano-Mooga S, Datta G, Wolkowicz P, Garber DW, Palgunachari M, White CR, Anantharamaiah GM.

Curr Top Pept Protein Res. 2018;19:15-25.

12.

Lipid-exchange in nanodiscs discloses membrane boundaries of cytochrome-P450 reductase.

Barnaba C, Ravula T, Medina-Meza IG, Im SC, Anantharamaiah GM, Waskell L, Ramamoorthy A.

Chem Commun (Camb). 2018 Jun 14;54(49):6336-6339. doi: 10.1039/c8cc02003e.

13.

A Minimal Functional Complex of Cytochrome P450 and FBD of Cytochrome P450 Reductase in Nanodiscs.

Prade E, Mahajan M, Im SC, Zhang M, Gentry KA, Anantharamaiah GM, Waskell L, Ramamoorthy A.

Angew Chem Int Ed Engl. 2018 Jul 9;57(28):8458-8462. doi: 10.1002/anie.201802210. Epub 2018 Jun 14.

14.

Cytochrome-P450-Induced Ordering of Microsomal Membranes Modulates Affinity for Drugs.

Barnaba C, Sahoo BR, Ravula T, Medina-Meza IG, Im SC, Anantharamaiah GM, Waskell L, Ramamoorthy A.

Angew Chem Int Ed Engl. 2018 Mar 19;57(13):3391-3395. doi: 10.1002/anie.201713167. Epub 2018 Feb 22.

15.

Membrane environment drives cytochrome P450's spin transition and its interaction with cytochrome b5.

Ravula T, Barnaba C, Mahajan M, Anantharamaiah GM, Im SC, Waskell L, Ramamoorthy A.

Chem Commun (Camb). 2017 Nov 28;53(95):12798-12801. doi: 10.1039/c7cc07520k.

16.

ApoA-I Mimetic Peptide 4F Reduces Age-Related Lipid Deposition in Murine Bruch's Membrane and Causes Its Structural Remodeling.

Rudolf M, Mir Mohi Sefat A, Miura Y, Tura A, Raasch W, Ranjbar M, Grisanti S, Aherrahrou Z, Wagner A, Messinger JD, Garber DW, Anantharamaiah GM, Curcio CA.

Curr Eye Res. 2018 Jan;43(1):135-146. doi: 10.1080/02713683.2017.1370118. Epub 2017 Oct 3.

PMID:
28972410
17.

Kinetic and Structural Characterization of the Effects of Membrane on the Complex of Cytochrome b 5 and Cytochrome c.

Gentry KA, Prade E, Barnaba C, Zhang M, Mahajan M, Im SC, Anantharamaiah GM, Nagao S, Waskell L, Ramamoorthy A.

Sci Rep. 2017 Aug 10;7(1):7793. doi: 10.1038/s41598-017-08130-7.

18.

Cholesterol reduction and macrophage function: role of paraoxonases.

White CR, Anantharamaiah GM.

Curr Opin Lipidol. 2017 Oct;28(5):397-402. doi: 10.1097/MOL.0000000000000444. Review.

19.

Apolipoprotein Mimetic Peptides as Modulators of Lipoprotein Function.

Anantharamaiah GM, Garber DW, White CR.

Protein Pept Lett. 2016;23(11):1024-1031.

PMID:
27586181
20.

Transintestinal transport of the anti-inflammatory drug 4F and the modulation of transintestinal cholesterol efflux.

Meriwether D, Sulaiman D, Wagner A, Grijalva V, Kaji I, Williams KJ, Yu L, Fogelman S, Volpe C, Bensinger SJ, Anantharamaiah GM, Shechter I, Fogelman AM, Reddy ST.

J Lipid Res. 2016 Jul;57(7):1175-93. doi: 10.1194/jlr.M067025. Epub 2016 May 19.

21.

High-density lipoprotein, mitochondrial dysfunction and cell survival mechanisms.

White CR, Giordano S, Anantharamaiah GM.

Chem Phys Lipids. 2016 Sep;199:161-169. doi: 10.1016/j.chemphyslip.2016.04.007. Epub 2016 May 2. Review.

22.

Recent developments in modulating atherogenic lipoproteins.

White CR, Goldberg DI, Anantharamaiah GM.

Curr Opin Lipidol. 2015 Oct;26(5):369-75. doi: 10.1097/MOL.0000000000000216. Review.

PMID:
26270809
23.

Efficacy of tomato concentrates in mouse models of dyslipidemia and cancer.

Chattopadhyay A, Grijalva V, Hough G, Su F, Mukherjee P, Farias-Eisner R, Anantharamaiah GM, Faull KF, Hwang LH, Navab M, Fogelman AM, Reddy ST.

Pharmacol Res Perspect. 2015 Aug;3(4):e00154. doi: 10.1002/prp2.154. Epub 2015 Jun 24.

24.

Novel method for reducing plasma cholesterol: a ligand replacement therapy.

Anantharamaiah GM, Goldberg D.

Clin Lipidol. 2015 Jan 1;10(1):83-90.

25.

Bioenergetic programming of macrophages by the apolipoprotein A-I mimetic peptide 4F.

Datta G, Kramer PA, Johnson MS, Sawada H, Smythies LE, Crossman DK, Chacko B, Ballinger SW, Westbrook DG, Mayakonda P, Anantharamaiah GM, Darley-Usmar VM, White CR.

Biochem J. 2015 May 1;467(3):517-27. doi: 10.1042/BJ20131635.

26.

Source and role of intestinally derived lysophosphatidic acid in dyslipidemia and atherosclerosis.

Navab M, Chattopadhyay A, Hough G, Meriwether D, Fogelman SI, Wagner AC, Grijalva V, Su F, Anantharamaiah GM, Hwang LH, Faull KF, Reddy ST, Fogelman AM.

J Lipid Res. 2015 Apr;56(4):871-87. doi: 10.1194/jlr.M056614. Epub 2015 Feb 2.

27.

Quantification of HDL particle concentration by calibrated ion mobility analysis.

Hutchins PM, Ronsein GE, Monette JS, Pamir N, Wimberger J, He Y, Anantharamaiah GM, Kim DS, Ranchalis JE, Jarvik GP, Vaisar T, Heinecke JW.

Clin Chem. 2014 Nov;60(11):1393-401. doi: 10.1373/clinchem.2014.228114. Epub 2014 Sep 15.

28.

Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review.

White CR, Garber DW, Anantharamaiah GM.

J Lipid Res. 2014 Oct;55(10):2007-21. doi: 10.1194/jlr.R051367. Epub 2014 Aug 25. Review.

29.

Apolipoprotein A-I mimetics.

Reddy ST, Navab M, Anantharamaiah GM, Fogelman AM.

Curr Opin Lipidol. 2014 Aug;25(4):304-8. doi: 10.1097/MOL.0000000000000092. Review.

30.

L-4F inhibits lipopolysaccharide-mediated activation of primary human neutrophils.

Sharifov OF, Xu X, Gaggar A, Tabengwa EM, White CR, Palgunachari MN, Anantharamaiah GM, Gupta H.

Inflammation. 2014 Oct;37(5):1401-12. doi: 10.1007/s10753-014-9864-7.

31.

Searching for a successful HDL-based treatment strategy.

Reddy ST, Navab M, Anantharamaiah GM, Fogelman AM.

Biochim Biophys Acta. 2014 Jan;1841(1):162-7. Review.

PMID:
24466591
32.

Comparison of anti-endotoxin activity of apoE and apoA mimetic derivatives of a model amphipathic peptide 18A.

Sharifov OF, Nayyar G, Ternovoy VV, Palgunachari MN, Garber DW, Anantharamaiah G, Gupta H.

Innate Immun. 2014 Nov;20(8):867-80. doi: 10.1177/1753425913514621. Epub 2013 Dec 9.

PMID:
24323453
33.

Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid.

Navab M, Hough G, Buga GM, Su F, Wagner AC, Meriwether D, Chattopadhyay A, Gao F, Grijalva V, Danciger JS, Van Lenten BJ, Org E, Lusis AJ, Pan C, Anantharamaiah GM, Farias-Eisner R, Smyth SS, Reddy ST, Fogelman AM.

J Lipid Res. 2013 Dec;54(12):3403-18. doi: 10.1194/jlr.M042051. Epub 2013 Oct 1.

34.

Cationic peptide mR18L with lipid lowering properties inhibits LPS-induced systemic and liver inflammation in rats.

Sharifov OF, Nayyar G, Ternovoy VV, Mishra VK, Litovsky SH, Palgunachari MN, Garber DW, Anantharamaiah GM, Gupta H.

Biochem Biophys Res Commun. 2013 Jul 12;436(4):705-10. doi: 10.1016/j.bbrc.2013.06.020. Epub 2013 Jun 17.

35.

Anti-inflammatory mechanisms of apolipoprotein A-I mimetic peptide in acute respiratory distress syndrome secondary to sepsis.

Sharifov OF, Xu X, Gaggar A, Grizzle WE, Mishra VK, Honavar J, Litovsky SH, Palgunachari MN, White CR, Anantharamaiah GM, Gupta H.

PLoS One. 2013 May 14;8(5):e64486. doi: 10.1371/journal.pone.0064486. Print 2013.

36.

In vivo and in vitro effects of an apolipoprotein e mimetic peptide on amyloid-β pathology.

Handattu SP, Monroe CE, Nayyar G, Palgunachari MN, Kadish I, van Groen T, Anantharamaiah GM, Garber DW.

J Alzheimers Dis. 2013;36(2):335-47. doi: 10.3233/JAD-122377.

37.

A novel approach to oral apoA-I mimetic therapy.

Chattopadhyay A, Navab M, Hough G, Gao F, Meriwether D, Grijalva V, Springstead JR, Palgnachari MN, Namiri-Kalantari R, Su F, Van Lenten BJ, Wagner AC, Anantharamaiah GM, Farias-Eisner R, Reddy ST, Fogelman AM.

J Lipid Res. 2013 Apr;54(4):995-1010. doi: 10.1194/jlr.M033555. Epub 2013 Feb 2. Erratum in: J Lipid Res. 2013 Nov;54(11):3220. Farias-Eisener, Robin [corrected to Farias-Eisener, Robin].

38.

Lipid complex of apolipoprotein A-I mimetic peptide 4F is a novel platform for paraoxonase-1 binding and enhancing its activity and stability.

Mishra VK, Palgunachari MN, McPherson DT, Anantharamaiah GM.

Biochem Biophys Res Commun. 2013 Jan 18;430(3):975-80. doi: 10.1016/j.bbrc.2012.11.128. Epub 2012 Dec 19.

39.

HDL Mimetic Peptide Administration Improves Left Ventricular Filling and Cardiac output in Lipopolysaccharide-Treated Rats.

Datta G, Gupta H, Zhang Z, Mayakonda P, Anantharamaiah GM, White CR.

J Clin Exp Cardiolog. 2011 Dec 22;2(172). pii: 1000172.

40.

Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice.

Handattu SP, Nayyar G, Garber DW, Palgunachari MN, Monroe CE, Keenum TD, Mishra VK, Datta G, Anantharamaiah GM.

Atherosclerosis. 2013 Mar;227(1):58-64. doi: 10.1016/j.atherosclerosis.2012.10.064. Epub 2012 Nov 2.

41.

Regulation of pattern recognition receptors by the apolipoprotein A-I mimetic peptide 4F.

White CR, Smythies LE, Crossman DK, Palgunachari MN, Anantharamaiah GM, Datta G.

Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2631-9. doi: 10.1161/ATVBAHA.112.300167. Epub 2012 Sep 13.

42.

Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice.

Nayyar G, Garber DW, Palgunachari MN, Monroe CE, Keenum TD, Handattu SP, Mishra VK, Anantharamaiah GM.

Atherosclerosis. 2012 Oct;224(2):326-31. doi: 10.1016/j.atherosclerosis.2012.05.040. Epub 2012 Jun 23.

43.

Preservation of biological function despite oxidative modification of the apolipoprotein A-I mimetic peptide 4F.

White CR, Datta G, Buck AK, Chaddha M, Reddy G, Wilson L, Palgunachari MN, Abbasi M, Anantharamaiah GM.

J Lipid Res. 2012 Aug;53(8):1576-87. doi: 10.1194/jlr.M026278. Epub 2012 May 15.

44.

Sidedness of interfacial arginine residues and anti-atherogenicity of apolipoprotein A-I mimetic peptides.

Nayyar G, Mishra VK, Handattu SP, Palgunachari MN, Shin R, McPherson DT, Deivanayagam CC, Garber DW, Segrest JP, Anantharamaiah GM.

J Lipid Res. 2012 May;53(5):849-58. doi: 10.1194/jlr.M019844. Epub 2012 Feb 29.

45.

D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice.

Navab M, Reddy ST, Anantharamaiah GM, Hough G, Buga GM, Danciger J, Fogelman AM.

J Lipid Res. 2012 Mar;53(3):437-45. doi: 10.1194/jlr.M023523. Epub 2011 Dec 13.

46.

Apolipoprotein E mimetics and cholesterol-lowering properties.

Sharifov OF, Nayyar G, Garber DW, Handattu SP, Mishra VK, Goldberg D, Anantharamaiah GM, Gupta H.

Am J Cardiovasc Drugs. 2011 Dec 1;11(6):371-81. doi: 10.2165/11594190-000000000-00000. Review.

PMID:
22149316
47.

Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasma.

Meriwether D, Imaizumi S, Grijalva V, Hough G, Vakili L, Anantharamaiah GM, Farias-Eisner R, Navab M, Fogelman AM, Reddy ST, Shechter I.

J Lipid Res. 2011 Oct;52(10):1795-809. doi: 10.1194/jlr.M016741. Epub 2011 Jul 29.

48.

Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally.

Navab M, Reddy ST, Anantharamaiah GM, Imaizumi S, Hough G, Hama S, Fogelman AM.

J Lipid Res. 2011 Jun;52(6):1200-10. doi: 10.1194/jlr.M013144. Epub 2011 Mar 28.

49.

D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD.

Ganapathy E, Su F, Meriwether D, Devarajan A, Grijalva V, Gao F, Chattopadhyay A, Anantharamaiah GM, Navab M, Fogelman AM, Reddy ST, Farias-Eisner R.

Int J Cancer. 2012 Mar 1;130(5):1071-81. doi: 10.1002/ijc.26079. Epub 2011 May 26.

50.

L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways.

Gao F, Vasquez SX, Su F, Roberts S, Shah N, Grijalva V, Imaizumi S, Chattopadhyay A, Ganapathy E, Meriwether D, Johnston B, Anantharamaiah GM, Navab M, Fogelman AM, Reddy ST, Farias-Eisner R.

Integr Biol (Camb). 2011 Apr;3(4):479-89. doi: 10.1039/c0ib00147c. Epub 2011 Feb 1.

Supplemental Content

Loading ...
Support Center